Healthcare - Biotechnology - NASDAQ - US
$ 86.83
-6.31 %
$ 10.8 B
Market Cap
-18.88
P/E
CASH FLOW STATEMENT
-297 M
OPERATING CASH FLOW
-773 M
INVESTING CASH FLOW
640 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Vaxcyte, Inc.
| Net Income | -402 M |
| Depreciation & Amortization | 10.2 M |
| Capital Expenditures | -67.9 M |
| Stock-Based Compensation | 48.8 M |
| Change in Working Capital | 81.3 M |
| Others | 35.3 M |
| Free Cash Flow | -365 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (402.3) | (223.5) | (100.1) | (89.2) | (50.3) | (29.5) | 17.2 K |
| Depreciation & Amortization | 10.2 | 9.2 | 3.5 | 1.4 | 1.2 | 1.0 | 625 |
| Deferred Income Tax | 0 | 0 | 0 | 0.3 | 1 K | 51 K | 0 |
| Stock Based Compensation | 48.8 | 23.6 | 10.7 | 5.4 | 1.2 | 0.7 | 390 |
| Other Operating Activities | (34.8) | 7.3 | 1.5 | 0.2 | (3.2) | (4.7) | 260 |
| Change in Working Capital | 81.3 | 12.7 | (37.0) | 35.3 | 3.9 | 1.9 | 1 K |
| Cash From Operations | (296.8) | (170.6) | (121.4) | (46.6) | (47.1) | (30.5) | 15 K |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (67.9) | (5.8) | (6.6) | (1.2) | (1.2) | (1.8) | 1.22 K |
| Other Items | (705.4) | 80.4 | (205.8) | 50 K | 0 | 1 K | 106 |
| Cash From Investing Activities | (773.3) | 74.6 | (212.3) | (1.1) | (1.2) | (1.8) | 1.12 K |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 61 K | (0.3) | (0.3) | (0.2) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.8 | 5.1 | 3.9 | 110.9 | 41.8 | 62.5 | 0.2 |
| Cash From Financing Activities | 639.8 | 861.5 | 17.8 | 374.9 | 41.6 | 62.2 | 43.9 K |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (437.0) | 765.7 | (316.3) | 327.2 | (7.1) | 30.0 | 27.8 K |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (364.7) | (176.4) | (127.9) | (47.8) | (48.3) | (32.2) | 16.2 K |